Site is Being Upgraded

Lifespan extension therapy: Epidermal growth factor (EGF) may increase life span via up-regulation of its target gene BubR1, 14/June/2018, 11.08 pm

Carbon monoxide-based therapy for autoimmune diabetes (TIDM): Carbon monoxide (CO) releasing molecules-2 (COR-M2) increases the expression of PD-L1, augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 13/June/2018, 9.23 am
June 13, 2018
Carbon monoxide-based therapy for body weight control, energy homeostasis and TIIDM: COR-M2( CO releasing molecule-2 )inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 14/June/2018, 11.18 pm
June 14, 2018
Show all

 What they say: Introduction: 

A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the journal  “EMBO”, by Prof Sinclair, North BJ, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:   Lifespan extension therapy: Epidermal growth factor (EGF) may increase life span via up-regulation of its target gene BubR1


From research findings to Therapeutic Opportunity: 

This study suggests, for the first time, that EGFby increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; and (b) regulate the expression of a number of longevity-promoting molecules (Fig. 1).

[easy_payment currency=”USD”]

Figure 1. EGF may extend  mammalian life span via up regulation of BuBR1 and down regulation of p70 S6 Kinase

Figure 2.  EGF functions as a longevity-promoter through induction of BuBR1

Thereby, it may: (1) increase insulin sensitivity; (2) attenuate cognitive impairment; (3) delay diseases of aging; (4) slow down cardiac aging; (5) promote resistance to bone, immune and motor dysfunction; (6) promote tissue rejuvenation; and (7) prolong median life span. Thus, pharmacological formulations encompassing “EGF  or its activators, either alone or in combination with other drugs, may be used to extend the lifespan of an individual (fig. 2).


Details on the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $300#

Undisclosed mechanistic information: How EGF increases the expression of BubR1 and extends mammalian life-span

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

# Research cooperation


References

Web: http://genomediscovery.org or http://newbioideas.com

CitationBoominathan, L., Lifespan extension therapy: Epidermal growth factor (EGF) may increase life span via up-regulation of its target gene BubR1, 14/June/2018, 11.10 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.